Regulatory T Cell-Based Adoptive Cell Therapy in Autoimmunity
International Journal of Molecular Sciences · 23.10.2025 · 26 (21) · 10340
DOI: 10.3390/ijms262110340 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.10.2025. Verfasst von Eduardo Gozálvez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Servei d'Immunologia, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, 08015 Barcelona, Spain. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Autoimmunity, Immunotherapy, Adoptive, Autoimmune Diseases. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 222 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Spanish Ministerio de Economía y Competitividad, European Development Regional Fund (ERDF) “A way to achieve Europe”.
Abstract (Originalsprache)
Regulatory T cells (Tregs) are a distinctive subset of CD4+ T cells critical in self-tolerance maintenance to prevent the development of autoimmunity. The mechanisms by which these cells provide immune regulation are numerous and, consequently, deeply involved in the pathogenesis of many autoimmune disorders. Treg-based adoptive cell transfer (ACT) therapy has generated interest as a novel, promising strategy to restore self-tolerance in autoimmunity. Polyclonal Treg-based ACT therapy was first implemented in clinical trials, presenting adequate safety profiles. Subsequent preclinical studies have shown antigen-specific Tregs to be safer and more effective than polyclonal approaches, so research has recently moved in this direction. Antigen-specificity can be conferred to Tregs by viral transduction of genes coding for engineered T cell receptors (eTCRs) or chimeric antigen receptors (CARs), with encouraging outcomes in different animal models of autoimmunity. This review focuses on the biology of Tregs, as well as on current preclinical and clinical data for Treg-based ACT in the field of autoimmunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servei d'Immunologia, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, 08015 Barcelona, Spain.
- Servei de Dermatologia, Hospital Clínic de Barcelona, 08015 Barcelona, Spain.
- Immunoreceptors of the Innate and Adaptive System, Institut d'Investigacions Biomèdiques August Pi I Sunyer, 08015 Barcelona, Spain.
- Department de Biomedicina, Universitat de Barcelona, 08015 Barcelona, Spain.
ORCID-Profile: Guillermo Muñoz-Sánchez, Francisco Lozano
Förderung
- Spanish Ministerio de Economía y Competitividad
- European Development Regional Fund (ERDF) “A way to achieve Europe”
Zitieren
APA
Gozálvez, E., Lario, A., Muñoz-Sánchez, G., & Lozano, F. (2025). Regulatory T Cell-Based Adoptive Cell Therapy in Autoimmunity. International Journal of Molecular Sciences, 26(21), 10340. https://doi.org/10.3390/ijms262110340
Vancouver
Gozálvez E, Lario A, Muñoz-Sánchez G, Lozano F. Regulatory T Cell-Based Adoptive Cell Therapy in Autoimmunity. International Journal of Molecular Sciences. 2025;26(21):10340. doi:10.3390/ijms262110340
BibTeX
@article{Gozlvez2025,
author = {Gozálvez, Eduardo and Lario, Adrián and Muñoz-Sánchez, Guillermo and Lozano, Francisco},
title = {Regulatory T Cell-Based Adoptive Cell Therapy in Autoimmunity},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {21},
pages = {10340},
doi = {10.3390/ijms262110340}
}
EUVIMED